Information Provided By:
Fly News Breaks for October 28, 2016
JAZZ
Oct 28, 2016 | 08:18 EDT
Leerink analyst Jason Gerberry lowered his price target for Jazz Pharmaceuticals to $178 from $202 on valuation. However, the analyst continues to recommend investors buy Jazz Pharmaceuticals' shares given the "strong" 2017 catalyst outlook, including a likely continuation of Xyrem patent settlements, favorable Phase 3 data for JZP-110 for excessive daytime sleepiness and approval of Vyxeos for secondary Acute Myeloid Leukemia. Gerberry reiterates an Outperform rating on the shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.